Xeris Biopharma (XERS) Expected to Post Earnings on Thursday

Posted by Brenda Bartman on Jul 30th, 2026

Xeris Biopharma (NASDAQ:XERS – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $90.1250 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Trading Up 1.7%

Shares of XERS stock opened at $8.38 on Thursday. Xeris Biopharma has a fifty-two week low of $4.87 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The stock has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $6.77. The company has a market cap of $1.45 billion, a P/E ratio of 139.67 and a beta of 0.62.

Insiders Place Their Bets

In other Xeris Biopharma news, Director Dawn Halkuff sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $121,800.00. Following the completion of the sale, the director owned 95,000 shares of the company’s stock, valued at approximately $578,550. This trade represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $6.06, for a total value of $101,002.02. Following the completion of the sale, the insider directly owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. This trade represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 251,500 shares of company stock valued at $1,846,457. 4.35% of the stock is currently owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma during the fourth quarter worth $25,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Xeris Biopharma by 179.3% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after buying an additional 5,000 shares during the last quarter. Truvestments Capital LLC grew its holdings in shares of Xeris Biopharma by 96.1% during the fourth quarter. Truvestments Capital LLC now owns 8,118 shares of the company’s stock valued at $64,000 after buying an additional 3,979 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at about $67,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Get Our Latest Stock Report on Xeris Biopharma

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.